Thelansis

 Cutaneous T-cell lymphoma (CTCL), or "skin T-cell lymphomas," makes up roughly 4 percent of all NHL cases. It primarily impacts the skin. In its initial phases, CTCL cells are predominantly located in the skin. As the disease advances in patients, these cells can accumulate in the bone marrow, bloodstream, lymph nodes, and solid organs. The two most common subtypes of CTCL are mycosis fungoides (MF), which tends to be slow-growing in early stages, and the more aggressive "Sézary syndrome" (SS). FDA-approved treatments for progressive, persistent, or recurring CTCLs include Vorinostat and romidepsin. When used as single agents, these drugs can achieve an overall response rate of 30% to 35%, with only 2% to 6% of cases experiencing a complete response. While chemotherapeutic agents treat CTCLs, they are associated with severe side effects. In the case of early-stage disorders, topical chemotherapeutic agents such as mechlorethamine (nitrogen mustard) and carmustine h...

  Cutaneous T-cell lymphoma (CTCL), or "skin T-cell lymphomas," account for about 4 percent of all cases of NHL and primarily affect the skin, as the term indicates. In the early stages, the CTCL cells are found primarily in the skin. In patients with advanced stages of the disease, the cells may accumulate in the marrow, blood, lymph nodes, and solid organs. Mycosis fungoides (MF), which is often indolent (slow-growing) in the early stages, and a more aggressive form known as "Sézary syndrome" The two most common subtypes of CTCL are mycosis fungoides (MF), which are often indolent (slow-growing) in early stages, and a more aggressive form called "Sézary syndrome" (SS) are the two most common subtypes of CTCL. Vorinostat and romidepsin are FDA-approved for treating progressive, persistent, or recurrent cutaneous t-cell lymphoma (CTCLs). When given as single agents, these agents can induce an overall response rate of 30% to 35%. Only 2 percent to 6 perce...